Eli Lilly & Co.

  • 3 Signs a Drug Will Fail

    By Brandy Betz - August 19, 2013 | Tickers: LLY, IPXL, VVUS

    Biotech and pharma investing often focuses on the potential approval and marketability of drugs. This can involve short-term investors trading on binary events or long-term investors weighing the marketability of several products to determine a company’s overall potential.

    A Food and Drug Administration approval doesn’t guarantee a product’s success. Some drugs are obviously heading out into a blockbuster market -- such as the all-oral hepatitis C treatments coming more »

  • Understanding The Massive Market Potential of Monoclonal Antibodies

    By Leo Sun - August 19, 2013 | Tickers: ABBV, LLY, JNJ, RHHBY

    Over the past several years, monoclonal antibodies have revolutionized cancer treatments. Monoclonal antibodies are laboratory-produced molecules which mimic naturally produced antibodies, forming the foundation of cutting edge oncology treatments, such as antibody drug conjugates (ADCs), biologics, and immunotherapy, which all aim to reduce or eliminate the use of traditional chemotherapy.

    Monoclonal antibodies, which are administered intravenously, have a wide variety of applications, including cancer cell marking, growth signal blocking, the more »

  • A Pharmacology Primer for the Biotech Investor

    By Seth Robey - August 16, 2013 | Tickers: LLY, MNKD, NVO, RHHBY

    In Pharmacology we don't only have to consider the actions of the drug on the body.  It is also important to understand the way the body processes the drug, or the Pharmacokinetics.  When you consider that drugs, like the nutrients in food, must be absorbed (A), distributed (D) throughout the body, metabolized (M), and excreted/eliminated (E), pharmacokinetics becomes a critical consideration in drug development.  Investors with a keen more »

  • Is This New Lung Cancer Treatment a Game Changer?

    By Leo Sun - August 16, 2013 | Tickers: LLY, PFE, RHHBY

    Eli Lilly (NYSE: LLY) rallied on Aug. 13 after the pharmaceutical giant announced that its Phase III trial for a lung cancer treatment had succeeded in increasing the overall survival rate of patients. Analysts immediately speculated that this new treatment could become a blockbuster drug, possibly softening the blow from the upcoming patent expiration of Lilly’s best-selling product, Cymbalta.

    Is this unexpected victory reason to pick up shares of more »

  • A Closer Look at the Controversial Market Growth of ADHD Treatments

    By Leo Sun - August 16, 2013 | Tickers: LLY, NVS, SHPG

    The existence of ADHD (attention deficit hyperactivity disorder) has been a hot button topic since the 1970s. On one hand, there are scientists who believe in treating it as a neurological disorder with pharmaceuticals, and on the other hand, there are parents, teachers and administrators who believe that ADHD is a behavioral, rather than psychological, issue. Accusations of kickback-induced over-prescriptions of ADHD medications, for both approved and off-label purposes more »

  • Positive News for This Troubled Pharma Player

    By Brandy Betz - August 15, 2013 | Tickers: LLY, MRK, SNY

    Eli Lilly (NYSE: LLY) closed last Tuesday up nearly 3% following positive phase 3 results for cancer drug necitumumab. The company had previously halted a different necitumumab trial for safety issues. This positive bit of news was particularly welcome in the wake of Lilly's late-stage pipeline crashes. And with two blockbuster drugs set to expire in the next year, Eli Lilly needs all the signs of strength it can more »

  • The Next Big Opportunity in Antidepressant Drugs

    By Kanak Kanti - August 14, 2013 | Tickers: LLY, FRX, PFE

    The economic cost to the country of 16 million depressed Americans is $44 billion every year. Depression, concomitant with a sedentary lifestyle, is becoming a global phenomenon. It is the leading cause of disability among all medical illnesses. Technically known as Major Depressive Disorder (MDD), depression has a number of medications that are neither very effective nor very safe. Fetzima, a newly FDA-approved drug from Forest Laboratories (NYSE: FRX), promises more »

  • Is This Biotech Stock Worth Buying After a Massive Post-IPO Surge?

    By Leo Sun - August 13, 2013 | Tickers: LLY, XON, ZIOP

    Synthetic biology startup Intrexon (NYSE: XON) surged 55% after its eagerly anticipated IPO hit the market on August 8. The company, which was founded by famed biotech company developer Randal J. “RJ” Kirk, raised $160 million from its initial offering of 10 million shares priced at $16 each.

    However, Intrexon doesn’t have any approved products on the market, and its revenue completely comes from its nine exclusive channel collaboration more »

  • Food Safety Concerns in China Could Fuel Zoetis’ Growth

    By Leo Sun - August 7, 2013 | Tickers: LLY, MRK, SFD, ZTS

    Zoetis (NYSE: ZTS), Pfizer’s former animal health business, has been on a roller coaster ride since its public debut in February. Pfizer spun off Zoetis in an effort to slim down its operations and boost revenue after the loss of patent exclusivity for its top selling cholesterol drug, Lipitor.

    <img alt="" src="http://media.ycharts.com/charts/ad01419297952b47597e75622f055e51.png" />

    Since then, the bulls and the bears are at odds regarding the future of Zoetis, and shares are still flat more »

  • These Pharmaceutical Giants Are Teetering Dangerously Near The Patent Cliff

    By Bob Ciura - August 2, 2013 | Tickers: BMY, LLY, PFE

    In the hunt for sustainable dividend yields, investors have rushed into the stocks of major pharmaceutical companies. These stocks are widely bought for their blue chip status and hefty dividend yields. Investors likely feel peace of mind buying these stocks, as medicine and health care are fairly recession-proof.

    At the same time, the industry is at an important inflection point. Several big pharma companies are struggling with patent cliffs, which more »

  • What You Need to Know About Dividends

    By Victor Lai - July 31, 2013 | Tickers: CVX, LLY, INTC

    When it comes to stock investing, conventional thinking dictates that returns are all about capital appreciation. However, for many investors, price appreciation may not be the main driver of total return at all. In fact, dividends can constitute a larger portion of total returns than many people may realize.

    Dividends Overlooked

    According to Loomis Sayles, almost 50% of the S&P 500's total return has come from dividends (when more »

  • Is This Company Getting Ahead of Itself?

    By Nicholas Kitonyi - July 30, 2013 | Tickers: LLY, JNJ, NVS, PFE

    The biotechnology industry is one of the riskiest places to put your money. However, when companies get everything right, the fortunes made there are usually massive. In the most recent quarter, biotech company Eli Lilly (NYSE: LLY) reported earnings that beat analyst estimates and boosted guidance for the next quarter and the current fiscal year.

    The company is counting on various products in the pipeline, which could change its outlook more »

  • A Fine Act of balancing by Sanofi

    By Shalini Agrawal - July 27, 2013 | Tickers: LLY, MRK, NVO, SNY


    In the history spanning more than two centuries, Sanofi (NYSE: SNY) has undergone number of major and minor changes to reach the level of integrated healthcare leader as it is today. To achieve this, Sanofi has been quick to spot the value-enhancing growth opportunities resulting in a number of mergers and acquisitions that the company has undertaken successfully.

    The company’s product lie into 3 major segments termed as Pharmaceuticals more »

  • Healthcare Stocks to Consider Buying

    By David Gould - July 26, 2013 | Tickers: ABT, ABBV, LLY, STJ

    Note: This article has been amended to remove TRADJENTA as Eli Lilly's leading products--it is developed and commercialized through an alliance between Eli Lilly and Boehringer Ingelheim International GmbH & Co

    To address the patent cliff, several large pharmaceutical companies have been actively reinventing their businesses in terms of pipeline updates and strategic changes. Below, I present my take on two leading producers with a focus on the headwinds and more »

  • What Does the Patent Cliff Mean for This Drugmaker?

    By Leo Sun - July 25, 2013 | Tickers: LLY, MRK, PFE

    For Eli Lilly (NYSE: LLY), history is repeating itself once again. The pharmaceutical company, which became a household name with its antidepressant Prozac in 1987, slipped in 2001 after it lost patent protection for its flagship drug. Over the following decade, Eli Lilly was unable to relive its Prozac-induced euphoria between 1987 and 2001, and shares have fallen nearly 30% over the past twelve years.

    <img alt="" src="http://media.ycharts.com/charts/41aa59dbcc774a165174f931dd3cc4be.png" />

    Later this year, Eli Lilly more »

  • You Should Be Concerned With These 4 Post-Earnings Stocks

    By Brian Nichols - July 25, 2013 | Tickers: CAT, LLY, RAI, STX

    Earnings can change the outlook for a company, good or bad, and they can also validate an opinion that you already may have. In the case of these four companies, earnings on Wednesday showcased significant concerns, and you should be careful before buying.

    Strong Presence, What About the Future?

    Eli Lilly (NYSE: LLY) traded higher by more than 3% after significantly beating Q2 earnings expectations. The company posted a 6 more »

  • Big Pharma’s Bribery Blues

    By Leo Sun - July 24, 2013 | Tickers: AZN, LLY, GSK, PFE

    Big pharmaceutical companies have a knack for getting into trouble with governments. Over the past four years, major names in big pharma - including Pfizer (NYSE: PFE), Novartis and GlaxoSmithKline (NYSE: GSK) - have been fined billions of dollars in the United States for giving physicians kickbacks and perks to promote off-label marketing.

    This month, charges of bribery have surfaced in China. The Chinese government is currently investigating GlaxoSmithKline for allegedly running more »

  • The Diabetes Pipeline With a Clog

    By Brandy Betz - July 22, 2013 | Tickers: AZN, BMY, LLY, JNJ

    Big pharma placed its bets on a new class of diabetes drugs called SGLT2. Last year, buzz surrounded late-stage projects from Johnson and Johnson (NYSE: JNJ), Eli Lilly (NYSE: LLY), and the partnership of Bristol-Myers Squibb (NYSE: BMY) and AstraZeneca (NYSE: AZN). But the path to market proved tricky.

    Johnson and Johnson's Invokana earlier this year became the first SGLT2 approved in the United States. Bristol-Myers and AstraZeneca’s more »

  • 3 Key Takeaways From JNJ's Q2

    By Brandy Betz - July 18, 2013 | Tickers: LLY, JNJ, VRTX

    Johnson & Johnson (NYSE: JNJ) reported its second quarter on Tuesday, and turned in some positive numbers. Revenue grew 8.5%, year-over-year, up to $17.9 billion. The EPS was higher than analyst estimates, and the company upped its full-year guidance.

    But the details are where things get interesting. Here are three key takeaways from the earnings report -- and what they mean for Johnson & Johnson’s future.

    1. Infectious disease and more »

  • The U.S. Antidepressant Market: Old Fashioned Branding Might Save the Day

    By Amod Saul - July 18, 2013 | Tickers: AZN, AZN, LLY, FRX, GSK, PFE, TRGT

    Over 40% of Americans have used an antidepressant at least once during their lifetime and, at 270 million prescriptions per year, antidepressants are the most consumed class of therapeutics in the US. However, revenue does not match prescription numbers due to fierce generic competition in the class. While retail prices for commonly prescribed branded anti-depressants like Cymbalta can reach over $170 per month, a generic equivalent will cost less than more »

  • Page 1 of 10